The FDA has approved a supplement to abbreviated new drug application ANDA205080, held by Amneal Pharmaceuticals, for itraconazole. An abbreviated application is the pathway for a generic of an already-approved product, and a supplement to one covers a change to an approved generic — a manufacturing site, a specification, a labelling revision — rather than any new clinical claim.
Nothing in the antifungal's indications, dosing or safety profile changes on the strength of this. It is reported here because the record carries the day's only regulatory activity for this desk, and because supply-side actions on generic antifungals are worth noticing for a different reason: itraconazole availability and quality directly affect the management of chronic pulmonary aspergillosis and of the extensive dermatophyte problem in India, where recalcitrant tinea has become routine.
The clinically relevant point about itraconazole remains what it has been. Absorption of the capsule formulation is erratic and food- and acid-dependent, interactions through CYP3A4 are extensive, and treatment failure in dermatophytosis is at least as often a pharmacokinetic problem as a resistance one.
- Take itraconazole capsules with food and an acidic drink; the solution formulation has different absorption requirements
- Review the full drug list for CYP3A4 interactions before starting — statins, some antiarrhythmics, several antiretrovirals
- Where itraconazole appears to be failing in dermatophytosis, check adherence and absorption before concluding resistance
- Note the brand dispensed where a patient's response changes without a change in prescription
Don't overread it
A supplement to an abbreviated application is an administrative approval — it is not a new indication, a new formulation claim or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free